| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
Bisphenol AF-d4 targets the same estrogen receptors (ER, specifically ERalpha) as its non-deuterated parent compound. Bisphenol AF acts as a full agonist of the estrogen receptor, binding to and activating this nuclear hormone receptor. This interaction can lead to the regulation of estrogen-responsive genes and mimic the effects of the natural hormone estrogen. This activity classifies it as an endocrine-disrupting chemical (EDC).
|
|---|---|
| ln Vitro |
Bisphenol AF-d4 is not typically used to assess biological activity, as its purpose is to serve as an analytical standard. The parent compound, Bisphenol AF, has been shown to be a full agonist of the estrogen receptor. It demonstrates potent estrogenic activity in vitro in transactivation assays using ERalpha-expressing cell lines, with an EC50 in the low nanomolar or sub-nanomolar range, comparable to or more potent than the natural hormone 17beta-estradiol.
|
| ln Vivo |
Bisphenol AF-d4 is not used to study biological efficacy in vivo, as it is a stable isotope-labeled standard. In contrast, the parent compound Bisphenol AF has been studied for its endocrine-disrupting effects in vivo. Animal studies have shown that exposure to Bisphenol AF can lead to estrogen-like effects, including the acceleration of puberty and the disruption of reproductive function in rodent models.
|
| Enzyme Assay |
As an analytical standard, Bisphenol AF-d4 is used in non-cellular assays involving mass spectrometry. The typical protocol involves spiking a known amount of Bisphenol AF-d4 into a sample (e.g., urine, serum, tissue homogenate, or environmental water). After sample preparation (such as liquid-liquid extraction or SPE), the mixture is analyzed by HPLC-MS/MS, and the compound is used to correct for matrix effects and extraction efficiency.
|
| Cell Assay |
Bisphenol AF-d4 is not used for in vitro cellular assays as a functional agent, but it can be used to quantify Bisphenol AF in cell lysates or culture media. For such an analytical application, cells are exposed to Bisphenol AF for a specified time. The media or cell lysate is then spiked with a known amount of Bisphenol AF-d4, processed, and analyzed by LC-MS/MS to determine the concentration of Bisphenol AF.
|
| Animal Protocol |
Bisphenol AF-d4 is used as an internal standard in in vivo toxicokinetic studies. An animal (e.g., rat or mouse) is administered Bisphenol AF orally or intravenously. Blood samples are collected at various time points, and plasma is separated. A known amount of Bisphenol AF-d4 is added to the plasma samples as an internal standard. The concentration of Bisphenol AF is then quantified using LC-MS/MS to generate pharmacokinetic parameters.
|
| ADME/Pharmacokinetics |
Bisphenol AF-d4 is a stable isotope-labeled compound used as an internal standard in LC-MS/MS analysis. It has a distinct molecular weight due to the replacement of four hydrogen atoms with deuterium (+4 Da). The compound is chemically stable under standard analytical conditions, and the deuterium labeling does not significantly alter its chromatographic behavior, allowing for co-elution with the analyte. It is soluble in DMSO and other organic solvents.
|
| Toxicity/Toxicokinetics |
Bisphenol AF-d4 is used as an analytical reference standard, and its direct toxicological profile is not reported. However, the parent compound Bisphenol AF is considered an endocrine-disrupting chemical with potential for reproductive toxicity and developmental toxicity. As a research-use chemical, standard laboratory safety precautions should be followed, including the use of personal protective equipment to avoid exposure.
|
| References | |
| Additional Infomation |
Bisphenol AF-d4 (BPAF-d4; 4,4'-(Perfluoropropane-2,2-diyl)diphenol-d4) has a molecular formula of C15H6D4F6O2 and a molecular weight of 340.25 g/mol. The deuterated atoms are located on the two phenol rings. The parent compound Bisphenol AF is a full agonist of the estrogen receptor and acts as an endocrine-disrupting chemical. The compound is typically stored as a solid powder at -20degC. It is for research use only.
|
| Molecular Formula |
C15H6D4F6O2
|
|---|---|
| Molecular Weight |
340.25
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9390 mL | 14.6951 mL | 29.3902 mL | |
| 5 mM | 0.5878 mL | 2.9390 mL | 5.8780 mL | |
| 10 mM | 0.2939 mL | 1.4695 mL | 2.9390 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
